ID   EPHA4_HUMAN             Reviewed;         986 AA.
AC   P54764; A8K2P1; B2R601; B7Z6Q8; Q2M380;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-OCT-2022, entry version 217.
DE   RecName: Full=Ephrin type-A receptor 4;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH-like kinase 8;
DE            Short=EK8;
DE            Short=hEK8;
DE   AltName: Full=Tyrosine-protein kinase TYRO1;
DE   AltName: Full=Tyrosine-protein kinase receptor SEK;
DE   Flags: Precursor;
GN   Name=EPHA4; Synonyms=HEK8, SEK, TYRO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=7898931;
RA   Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R.,
RA   Welcher A.A.;
RT   "cDNA cloning and tissue distribution of five human EPH-like receptor
RT   protein-tyrosine kinases.";
RL   Oncogene 10:897-905(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Amygdala, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [6]
RP   INTERACTION WITH SIPA1L1.
RX   PubMed=18094260; DOI=10.1523/jneurosci.2746-07.2007;
RA   Richter M., Murai K.K., Bourgin C., Pak D.T., Pasquale E.B.;
RT   "The EphA4 receptor regulates neuronal morphology through SPAR-mediated
RT   inactivation of Rap GTPases.";
RL   J. Neurosci. 27:14205-14215(2007).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF CDK5, AND AUTOPHOSPHORYLATION.
RX   PubMed=17143272; DOI=10.1038/nn1811;
RA   Fu W.Y., Chen Y., Sahin M., Zhao X.S., Shi L., Bikoff J.B., Lai K.O.,
RA   Yung W.H., Fu A.K., Greenberg M.E., Ip N.Y.;
RT   "Cdk5 regulates EphA4-mediated dendritic spine retraction through an
RT   ephexin1-dependent mechanism.";
RL   Nat. Neurosci. 10:67-76(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 29-209.
RX   PubMed=18708347; DOI=10.1074/jbc.m804114200;
RA   Qin H., Shi J., Noberini R., Pasquale E.B., Song J.;
RT   "Crystal structure and NMR binding reveal that two small molecule
RT   antagonists target the high affinity ephrin-binding channel of the EphA4
RT   receptor.";
RL   J. Biol. Chem. 283:29473-29484(2008).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 30-202 IN COMPLEX WITH EFNA2 OR
RP   EFNB2, AND LIGAND-BINDING.
RX   PubMed=19836338; DOI=10.1016/j.str.2009.07.018;
RA   Bowden T.A., Aricescu A.R., Nettleship J.E., Siebold C., Rahman-Huq N.,
RA   Owens R.J., Stuart D.I., Jones E.Y.;
RT   "Structural plasticity of EPH receptor A4 facilitates cross-class ephrin
RT   signaling.";
RL   Structure 17:1386-1397(2009).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 29-203 IN COMPLEX WITH EFNB2, AND
RP   MUTAGENESIS OF GLN-40 AND GLU-42.
RX   PubMed=19875447; DOI=10.1074/jbc.m109.064824;
RA   Qin H., Noberini R., Huan X., Shi J., Pasquale E.B., Song J.;
RT   "Structural characterization of the EphA4-Ephrin-B2 complex reveals new
RT   features enabling Eph-ephrin binding promiscuity.";
RL   J. Biol. Chem. 285:644-654(2010).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-269; GLU-370 AND PHE-399.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds membrane-bound ephrin
CC       family ligands residing on adjacent cells, leading to contact-dependent
CC       bidirectional signaling into neighboring cells. The signaling pathway
CC       downstream of the receptor is referred to as forward signaling while
CC       the signaling pathway downstream of the ephrin ligand is referred to as
CC       reverse signaling. Highly promiscuous, it has the unique property among
CC       Eph receptors to bind and to be physiologically activated by both GPI-
CC       anchored ephrin-A and transmembrane ephrin-B ligands including EFNA1
CC       and EFNB3. Upon activation by ephrin ligands, modulates cell morphology
CC       and integrin-dependent cell adhesion through regulation of the Rac, Rap
CC       and Rho GTPases activity. Plays an important role in the development of
CC       the nervous system controlling different steps of axonal guidance
CC       including the establishment of the corticospinal projections. May also
CC       control the segregation of motor and sensory axons during neuromuscular
CC       circuit development. In addition to its role in axonal guidance plays a
CC       role in synaptic plasticity. Activated by EFNA1 phosphorylates CDK5 at
CC       'Tyr-15' which in turn phosphorylates NGEF regulating RHOA and
CC       dendritic spine morphogenesis. In the nervous system, also plays a role
CC       in repair after injury preventing axonal regeneration and in
CC       angiogenesis playing a role in central nervous system vascular
CC       formation. Additionally, its promiscuity makes it available to
CC       participate in a variety of cell-cell signaling regulating for instance
CC       the development of the thymic epithelium. During development of the
CC       cochlear organ of Corti, regulates pillar cell separation by forming a
CC       ternary complex with ADAM10 and CADH1 which facilitates the cleavage of
CC       CADH1 by ADAM10 and disruption of adherens junctions (By similarity).
CC       {ECO:0000250|UniProtKB:Q03137, ECO:0000269|PubMed:17143272}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer
CC       is composed of an ephrin dimer and a receptor dimer. Oligomerization is
CC       probably required to induce biological responses. Interacts
CC       (phosphorylated at position Tyr-602) with FYN. Interacts with CDK5,
CC       CDK5R1 and NGEF; upon activation by EFNA1 induces NGEF phosphorylation
CC       by the kinase CDK5. Interacts with CHN1; effector of EPHA4 in axon
CC       guidance linking EPHA4 activation to RAC1 regulation (By similarity).
CC       Interacts (via PDZ motif) with SIPA1L1 (via PDZ domain); controls
CC       neuronal morphology through regulation of the RAP1 (RAP1A or RAP1B) and
CC       RAP2 (RAP2A, RAP2B or RAP2C) GTPases. Forms a ternary complex composed
CC       of ADAM10, CADH1 and EPHA4; within the complex, CADH1 is cleaved by
CC       ADAM10 which disrupts adherens junctions (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q03137, ECO:0000269|PubMed:18094260,
CC       ECO:0000269|PubMed:19836338, ECO:0000269|PubMed:19875447}.
CC   -!- INTERACTION:
CC       P54764; O43921: EFNA2; NbExp=4; IntAct=EBI-5773557, EBI-8603210;
CC       P54764; P52803: EFNA5; NbExp=2; IntAct=EBI-5773557, EBI-1753674;
CC       P54764; P52799: EFNB2; NbExp=4; IntAct=EBI-5773557, EBI-7532268;
CC       P54764; Q15768: EFNB3; NbExp=2; IntAct=EBI-5773557, EBI-3908475;
CC       P54764; P29323: EPHB2; NbExp=3; IntAct=EBI-5773557, EBI-1059294;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}. Cell projection, axon {ECO:0000250}.
CC       Cell projection, dendrite {ECO:0000250}. Postsynaptic density membrane
CC       {ECO:0000250}. Early endosome {ECO:0000250}. Cell junction, adherens
CC       junction {ECO:0000250|UniProtKB:Q03137}. Note=Clustered upon activation
CC       and targeted to early endosome. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P54764-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54764-2; Sequence=VSP_056016;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: The protein kinase domain mediates interaction with NGEF.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L36645; AAA74246.1; -; mRNA.
DR   EMBL; AK290306; BAF82995.1; -; mRNA.
DR   EMBL; AK300772; BAH13344.1; -; mRNA.
DR   EMBL; AK312380; BAG35298.1; -; mRNA.
DR   EMBL; AC010899; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079834; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC105000; AAI05001.1; -; mRNA.
DR   EMBL; BC105002; AAI05003.1; -; mRNA.
DR   CCDS; CCDS2447.1; -. [P54764-1]
DR   PIR; I78844; I78844.
DR   RefSeq; NP_001291465.1; NM_001304536.1. [P54764-1]
DR   RefSeq; NP_001291466.1; NM_001304537.1. [P54764-2]
DR   RefSeq; NP_004429.1; NM_004438.4. [P54764-1]
DR   PDB; 2LW8; NMR; -; A=29-209.
DR   PDB; 2WO1; X-ray; 1.85 A; A/B=30-202.
DR   PDB; 2WO2; X-ray; 2.45 A; A=30-202.
DR   PDB; 2WO3; X-ray; 2.35 A; A=30-202.
DR   PDB; 3CKH; X-ray; 2.80 A; A/B=29-209.
DR   PDB; 3GXU; X-ray; 2.50 A; A=29-203.
DR   PDB; 4BK4; X-ray; 3.65 A; A/B=20-547.
DR   PDB; 4BK5; X-ray; 4.00 A; A=20-547.
DR   PDB; 4BKA; X-ray; 5.30 A; A=20-547.
DR   PDB; 4BKF; X-ray; 4.65 A; A/B=20-547.
DR   PDB; 4M4P; X-ray; 2.08 A; A=27-543.
DR   PDB; 4M4R; X-ray; 3.13 A; A/C/E/G=27-543.
DR   PDB; 4W4Z; X-ray; 2.41 A; A/B/C/D=29-204.
DR   PDB; 4W50; X-ray; 2.42 A; A/B/C/D=29-204.
DR   PDB; 5JR2; X-ray; 1.75 A; A/B/C/D=29-204.
DR   PDB; 7OFV; X-ray; 1.43 A; A=29-209.
DR   PDBsum; 2LW8; -.
DR   PDBsum; 2WO1; -.
DR   PDBsum; 2WO2; -.
DR   PDBsum; 2WO3; -.
DR   PDBsum; 3CKH; -.
DR   PDBsum; 3GXU; -.
DR   PDBsum; 4BK4; -.
DR   PDBsum; 4BK5; -.
DR   PDBsum; 4BKA; -.
DR   PDBsum; 4BKF; -.
DR   PDBsum; 4M4P; -.
DR   PDBsum; 4M4R; -.
DR   PDBsum; 4W4Z; -.
DR   PDBsum; 4W50; -.
DR   PDBsum; 5JR2; -.
DR   PDBsum; 7OFV; -.
DR   AlphaFoldDB; P54764; -.
DR   SMR; P54764; -.
DR   BioGRID; 108357; 80.
DR   DIP; DIP-48294N; -.
DR   IntAct; P54764; 160.
DR   MINT; P54764; -.
DR   STRING; 9606.ENSP00000281821; -.
DR   BindingDB; P54764; -.
DR   ChEMBL; CHEMBL3988; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P54764; -.
DR   GuidetoPHARMACOLOGY; 1824; -.
DR   GlyGen; P54764; 4 sites.
DR   iPTMnet; P54764; -.
DR   PhosphoSitePlus; P54764; -.
DR   BioMuta; EPHA4; -.
DR   DMDM; 1711371; -.
DR   CPTAC; CPTAC-2790; -.
DR   EPD; P54764; -.
DR   jPOST; P54764; -.
DR   MassIVE; P54764; -.
DR   MaxQB; P54764; -.
DR   PaxDb; P54764; -.
DR   PeptideAtlas; P54764; -.
DR   PRIDE; P54764; -.
DR   ProteomicsDB; 56717; -. [P54764-1]
DR   TopDownProteomics; P54764-1; -. [P54764-1]
DR   ABCD; P54764; 11 sequenced antibodies.
DR   Antibodypedia; 34350; 713 antibodies from 37 providers.
DR   DNASU; 2043; -.
DR   Ensembl; ENST00000281821.7; ENSP00000281821.2; ENSG00000116106.12. [P54764-1]
DR   Ensembl; ENST00000409938.5; ENSP00000386829.1; ENSG00000116106.12. [P54764-1]
DR   GeneID; 2043; -.
DR   KEGG; hsa:2043; -.
DR   MANE-Select; ENST00000281821.7; ENSP00000281821.2; NM_004438.5; NP_004429.1.
DR   UCSC; uc002vmq.4; human. [P54764-1]
DR   CTD; 2043; -.
DR   DisGeNET; 2043; -.
DR   GeneCards; EPHA4; -.
DR   HGNC; HGNC:3388; EPHA4.
DR   HPA; ENSG00000116106; Tissue enhanced (choroid).
DR   MalaCards; EPHA4; -.
DR   MIM; 602188; gene.
DR   neXtProt; NX_P54764; -.
DR   OpenTargets; ENSG00000116106; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   PharmGKB; PA27820; -.
DR   VEuPathDB; HostDB:ENSG00000116106; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000156948; -.
DR   InParanoid; P54764; -.
DR   OMA; TENSRPN; -.
DR   PhylomeDB; P54764; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P54764; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P54764; -.
DR   SIGNOR; P54764; -.
DR   BioGRID-ORCS; 2043; 17 hits in 1108 CRISPR screens.
DR   ChiTaRS; EPHA4; human.
DR   EvolutionaryTrace; P54764; -.
DR   GeneWiki; EPH_receptor_A4; -.
DR   GenomeRNAi; 2043; -.
DR   Pharos; P54764; Tchem.
DR   PRO; PR:P54764; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P54764; protein.
DR   Bgee; ENSG00000116106; Expressed in Brodmann (1909) area 23 and 186 other tissues.
DR   ExpressionAtlas; P54764; baseline and differential.
DR   Genevisible; P54764; HS.
DR   GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0044295; C:axonal growth cone; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0043198; C:dendritic shaft; ISS:ARUK-UCL.
DR   GO; GO:0043197; C:dendritic spine; ISS:ARUK-UCL.
DR   GO; GO:0031901; C:early endosome membrane; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0030175; C:filopodium; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098839; C:postsynaptic density membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0001540; F:amyloid-beta binding; TAS:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0097161; F:DH domain binding; IDA:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IGI:ARUK-UCL.
DR   GO; GO:0042731; F:PH domain binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0034332; P:adherens junction organization; IEA:Ensembl.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; ISS:ARUK-UCL.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0021957; P:corticospinal tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0097156; P:fasciculation of motor neuron axon; ISS:UniProtKB.
DR   GO; GO:0097155; P:fasciculation of sensory neuron axon; ISS:UniProtKB.
DR   GO; GO:0008347; P:glial cell migration; IEA:Ensembl.
DR   GO; GO:0008045; P:motor neuron axon guidance; ISS:UniProtKB.
DR   GO; GO:0048681; P:negative regulation of axon regeneration; ISS:UniProtKB.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IMP:ARUK-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:ARUK-UCL.
DR   GO; GO:1900038; P:negative regulation of cellular response to hypoxia; IMP:ARUK-UCL.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:ARUK-UCL.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IDA:ARUK-UCL.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; ISS:ARUK-UCL.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL.
DR   GO; GO:1903051; P:negative regulation of proteolysis involved in protein catabolic process; IGI:ARUK-UCL.
DR   GO; GO:0072178; P:nephric duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0106030; P:neuron projection fasciculation; ISS:ARUK-UCL.
DR   GO; GO:0097485; P:neuron projection guidance; ISS:ARUK-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:1902004; P:positive regulation of amyloid-beta formation; IGI:ARUK-UCL.
DR   GO; GO:1902961; P:positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process; IGI:ARUK-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:ARUK-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:ARUK-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IGI:ARUK-UCL.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; ISS:ARUK-UCL.
DR   GO; GO:2001108; P:positive regulation of Rho guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IGI:ARUK-UCL.
DR   GO; GO:0048710; P:regulation of astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0050770; P:regulation of axonogenesis; ISS:UniProtKB.
DR   GO; GO:0061001; P:regulation of dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:1905244; P:regulation of modification of synaptic structure; ISS:ARUK-UCL.
DR   GO; GO:0098883; P:synapse pruning; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10482; EphR_LBD_A4; 1.
DR   CDD; cd00063; FN3; 2.
DR   CDD; cd09545; SAM_EPH-A4; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034270; EphA4_rcpt_lig-bd.
DR   InterPro; IPR030602; EphA4_SAM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell junction; Cell membrane; Cell projection; Developmental protein;
KW   Endosome; Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Reference proteome;
KW   Repeat; Signal; Synapse; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   CHAIN           20..986
FT                   /note="Ephrin type-A receptor 4"
FT                   /id="PRO_0000016807"
FT   TOPO_DOM        20..547
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        548..569
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        570..986
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          30..209
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          328..439
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          440..537
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          621..882
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          911..975
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   MOTIF           984..986
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        746
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         627..635
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         653
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         596
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q03137"
FT   MOD_RES         602
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q03137"
FT   MOD_RES         779
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         928
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        235
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        340
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        408
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        545
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..53
FT                   /note="MAGIFYFALFSCLFGICDAVTGSRVYPANEVTLLDSRSVQGELGWIASPLEG
FT                   G -> MK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056016"
FT   VARIANT         269
FT                   /note="R -> Q (in dbSNP:rs35084379)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042135"
FT   VARIANT         370
FT                   /note="G -> E (in a bladder carcinoma NOS sample; somatic
FT                   mutation; dbSNP:rs756952113)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042136"
FT   VARIANT         399
FT                   /note="S -> F (in a metastatic melanoma sample; somatic
FT                   mutation; dbSNP:rs868224085)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042137"
FT   VARIANT         953
FT                   /note="R -> K (in dbSNP:rs35341687)"
FT                   /id="VAR_049721"
FT   MUTAGEN         40
FT                   /note="Q->A: 10-fold reduced affinity for EFNB2; when
FT                   associated with A-42."
FT                   /evidence="ECO:0000269|PubMed:19875447"
FT   MUTAGEN         42
FT                   /note="E->A: 10-fold reduced affinity for EFNB2; when
FT                   associated with A-40."
FT                   /evidence="ECO:0000269|PubMed:19875447"
FT   CONFLICT        71
FT                   /note="Q -> P (in Ref. 2; BAF82995)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        102
FT                   /note="K -> R (in Ref. 2; BAF82995)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        137
FT                   /note="I -> V (in Ref. 2; BAG35298)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        362
FT                   /note="Y -> H (in Ref. 2; BAF82995)"
FT                   /evidence="ECO:0000305"
FT   STRAND          29..35
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   HELIX           36..38
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   TURN            40..42
FT                   /evidence="ECO:0007829|PDB:4M4R"
FT   STRAND          46..53
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          55..60
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          62..65
FT                   /evidence="ECO:0007829|PDB:2LW8"
FT   STRAND          66..72
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          77..79
FT                   /evidence="ECO:0007829|PDB:5JR2"
FT   STRAND          82..85
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          93..96
FT                   /evidence="ECO:0007829|PDB:2LW8"
FT   STRAND          97..105
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   HELIX           108..110
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          114..116
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          119..130
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          131..133
FT                   /evidence="ECO:0007829|PDB:2LW8"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          142..149
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          154..159
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          162..173
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          178..190
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          192..203
FT                   /evidence="ECO:0007829|PDB:7OFV"
FT   STRAND          207..209
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          212..214
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          226..230
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          237..248
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          257..262
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          266..269
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          272..275
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          304..306
FT                   /evidence="ECO:0007829|PDB:4M4R"
FT   STRAND          333..340
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          343..349
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          361..368
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   TURN            373..375
FT                   /evidence="ECO:0007829|PDB:4M4R"
FT   STRAND          385..388
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          390..393
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          395..401
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          405..416
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          418..423
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   HELIX           426..428
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          429..435
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          447..452
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          457..461
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          473..483
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          489..500
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          508..517
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   STRAND          528..531
FT                   /evidence="ECO:0007829|PDB:4M4P"
FT   TURN            538..540
FT                   /evidence="ECO:0007829|PDB:4M4P"
SQ   SEQUENCE   986 AA;  109860 MW;  0C39C1152EDDD46F CRC64;
     MAGIFYFALF SCLFGICDAV TGSRVYPANE VTLLDSRSVQ GELGWIASPL EGGWEEVSIM
     DEKNTPIRTY QVCNVMEPSQ NNWLRTDWIT REGAQRVYIE IKFTLRDCNS LPGVMGTCKE
     TFNLYYYESD NDKERFIREN QFVKIDTIAA DESFTQVDIG DRIMKLNTEI RDVGPLSKKG
     FYLAFQDVGA CIALVSVRVF YKKCPLTVRN LAQFPDTITG ADTSSLVEVR GSCVNNSEEK
     DVPKMYCGAD GEWLVPIGNC LCNAGHEERS GECQACKIGY YKALSTDATC AKCPPHSYSV
     WEGATSCTCD RGFFRADNDA ASMPCTRPPS APLNLISNVN ETSVNLEWSS PQNTGGRQDI
     SYNVVCKKCG AGDPSKCRPC GSGVHYTPQQ NGLKTTKVSI TDLLAHTNYT FEIWAVNGVS
     KYNPNPDQSV SVTVTTNQAA PSSIALVQAK EVTRYSVALA WLEPDRPNGV ILEYEVKYYE
     KDQNERSYRI VRTAARNTDI KGLNPLTSYV FHVRARTAAG YGDFSEPLEV TTNTVPSRII
     GDGANSTVLL VSVSGSVVLV VILIAAFVIS RRRSKYSKAK QEADEEKHLN QGVRTYVDPF
     TYEDPNQAVR EFAKEIDASC IKIEKVIGVG EFGEVCSGRL KVPGKREICV AIKTLKAGYT
     DKQRRDFLSE ASIMGQFDHP NIIHLEGVVT KCKPVMIITE YMENGSLDAF LRKNDGRFTV
     IQLVGMLRGI GSGMKYLSDM SYVHRDLAAR NILVNSNLVC KVSDFGMSRV LEDDPEAAYT
     TRGGKIPIRW TAPEAIAYRK FTSASDVWSY GIVMWEVMSY GERPYWDMSN QDVIKAIEEG
     YRLPPPMDCP IALHQLMLDC WQKERSDRPK FGQIVNMLDK LIRNPNSLKR TGTESSRPNT
     ALLDPSSPEF SAVVSVGDWL QAIKMDRYKD NFTAAGYTTL EAVVHVNQED LARIGITAIT
     HQNKILSSVQ AMRTQMQQMH GRMVPV
//
